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Introduction: Right-sided colon cancer (RSCC) and left-sided colorectal cancer (LSCRC) differ with respect to their
biology and genomic patterns. This study aimed to examine whether the primary tumor location is associated with
the response to cetuximab in patients with metastatic colorectal cancer (mCRC).
Methods: Patients with mCRC treated with cetuximab and standard chemotherapy as first- or second-line treatments
were compared with randomly chosen patients who were treated with chemotherapy alone between 2005 and 2013.
The main outcome measures were the overall response rate (ORR), progression-free survival (PFS), and overall survival (OS).
The differences in the outcome were analyzed by using the chi-squared test, Student’s t test, and Kaplan-Meier method.
Results: The treatment results of 206 patients with mCRC treated with cetuximab and standard chemotherapy as
first- or second-line treatments were compared with those of 210 patients who were treated with chemotherapy
alone. As a first-line treatment, cetuximab with chemotherapy was associated with a significantly higher ORR
(49.4 % vs. 28.6 %, P = 0.005) as well as longer PFS (9.1 vs. 6.2 months, P = 0.002) and OS (28.9 vs. 20.1 months,
P = 0.036) than chemotherapy alone in patients with LSCRC. However, cetuximab neither improved the ORR
(36.4 % vs. 26.2 %, P = 0.349) nor prolonged PFS (5.6 vs. 5.7 months, P = 0.904) or OS (25.1 vs. 19.8 months, P = 0.553) in
patients with RSCC. As a second-line treatment, cetuximab exhibited a tendency to improve the ORR (23.5 % vs. 10.2 %,
P = 0.087) and prolong PFS (4.9 vs. 3.5 months, P = 0.064), and it significantly prolonged OS (17.1 vs. 12.4 months,
P = 0.047) compared with chemotherapy alone in the patients with LSCRC. In contrast, as a second-line treatment,
cetuximab neither improved the ORR (7.1 % vs. 11.4 %, P = 0.698) nor prolonged PFS (3.3 vs. 4.2 months, P = 0.761) or
OS (13.4 vs. 13.0 months, P = 0.652) in patients with RSCC.
Conclusions: The addition of cetuximab to chemotherapy in both first- and second-line treatments of mCRC may only
benefit patients with primary LSCRC.
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Colorectal carcinomas (CRCs) that occur proximal
(right) or distal (left) to the splenic flexure exhibit differ-
ences in their embryologic development, blood supply,
macroscopic pathology, and clinicopathologic parameters
[1, 2]. The right colon arises from the embryonic midgut* Correspondence: liyh@sysucc.org.cn; xurh@sysucc.org.cn
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(http://creativecommons.org/publicdomain/zeand is perfused by the superior mesenteric artery, whereas
the left colon originates from the hindgut and is served by
the inferior mesenteric artery [2]. Right-sided colon can-
cers (RSCCs) are typically bulky, exophytic, polypoid le-
sions that project into the lumen and cause significant
anemia, whereas left-sided colorectal cancers (LSCRCs)
are typically infiltrating, constricting lesions that encircle
the lumen, often leading to obstruction [1]. Poorly differ-
entiated adenocarcinoma or signet-ring cell carcinoma
and mucinous adenocarcinoma are more frequently seen
in the right colon than in the left colon [3]. RSCCs typic-
ally present at a more advanced stage, and the patientsicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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tients with LSCRCs [4–6].
Recent studies have revealed distinguishable genomic
patterns between LSCRC and RSCC [7, 8]. LSCRCs ex-
hibit higher p53 gene mutation and cyclooxygenase-2
expression rates with more common chromosomal in-
stability [9–12]. RSCCs are generally diploid, and they
exhibit higher rates of microsatellite instability (MSI)
and higher expression of cytoplasmic c-erbB2 and epi-
dermal growth factor receptors (EGFRs) [13]. Recent
whole genome analysis has shown that RSCCs are more
likely to be hypermethylated as well as to have elevated
mutation rates compared with LSCRCs [7]. Some studies
have reported significantly more activating mutations in
codon 12/13 of Kirsten rat sarcoma viral oncogeneTable 1 Baseline clinicopathologic characteristics of patients with fir
Clinicopathologic characteristic Cetuximab group
All patients RSCC LSCRC
No. of patients 110 33 77
Median age at diagnosis
≤65 years 90 (81.8) 29 (87.9) 62 (80.5)
>65 years 20 (18.2) 4 (12.1) 15 (19.5)
Sex
Male 75 (68.2) 20 (60.6) 55 (71.4)
Female 35 (31.8) 13 (39.4) 22 (28.6)
ECOG performance status
0 49 (44.5) 11 (33.3) 38 (49.4)
1 58 (52.7) 21 (63.6) 37 (48.1)
≥2 3 (2.7) 1 (3.0) 2 (2.6)
Pathology
Adenocarcinoma 101 (91.8) 26 (78.8) 75 (97.4)
Mucinous & signet-ring cell 9 (8.2) 7 (21.2) 2 (2.6)
Metastasis
Single 67 (60.9) 19 (57.6) 48 (62.3)
Multiple 43 (39.1) 14 (42.4) 29 (37.7)
Metastasis resection 29 (26.4) 6 (18.2) 23 (29.9)
Total cycles of cetuximaba 8 (2–29) 9 (2–29) 8 (2–29)
Total cycles of chemotherapya 13 (2–43) 13 (3–38) 13 (2–43)
All three active drugsb 73 (66.4) 24 (72.7) 49 (63.6)
Backbone chemotherapy
Oxaliplatin-based 37 (33.6) 6 (18.2) 31 (40.3)
Irinotecan-based 73 (66.4) 27 (81.8) 46 (59.7)
Bevacizumab during the disease 44 (40.0) 15 (45.5) 29 (37.7)
Recurrent diseasec 31 (28.2) 6 (18.2) 25 (32.5)
aThe values are presented as median followed by range in parentheses; other value
parentheses. b Patients who received 5-fluorouracil, oxaliplatin, and irinotecan durin
curative-intent primary tumor resection. d Patient characteristics were compared be
Oncology Group; RSCC, right-sided colon cancer; LSCRC, left-sided colorectal cancerhomolog (KRAS) in RSCCs than in LSCRCs [14, 15].
However, other studies have reported that there is no
substantial difference in the KRAS mutations between
RSCCs and LSCRCs [8, 16]. LSCRCs exhibit a significant
association between KRAS activation and distant organ
metastasis, whereas RSCCs do not. Mutation of KRAS
was found to be associated with a significantly poorer
prognosis in patients with LSCRCs, but not in those
with RSCCs [17].
Cetuximab is a chimeric IgG1 monoclonal antibody
that binds to the extracellular domain of EGFR; also, it
blocks ligand-induced receptor signaling and induces
immune-mediated antitumor mechanisms, such as
antibody-dependent cell-mediated cytotoxicity [18, 19].
Cetuximab is currently approved for the treatment ofst-line treatment
Chemotherapy alone group P value d
P value All patients RSCC LSCRC P value
– 117 61 56 – 0.001*
0.420 0.502 0.613
93 (79.5) 50 (82.0) 43 (76.8)
24 (20.5) 11 (18.0) 13 (23.2)
0.274 0.085 0.404
73 (62.4) 43 (70.5) 30 (53.6)
44 (37.6) 18 (29.5) 26 (46.4)
0.300 0.367 0.113
49 (41.9) 29 (47.5) 20 (35.7)
57 (48.7) 26 (42.6) 31 (55.4)
11 (9.4) 6 (9.8) 5 (8.9)
0.003* 0.116 0.608
110 (94.0) 55 (90.2) 55 (98.2)
7 (6.0) 6 (9.8) 1 (1.8)
0.674 0.015* 0.893
70 (59.8) 43 (70.5) 27 (48.2)
47 (40.2) 18 (29.5) 29 (51.8)
0.244 28 (23.9) 15 (24.6) 13 (23.2) 1.000 0.760
0.537 – – – – –
0.928 13 (2–38) 14 (2–38) 13 (4–38) 0.546 0.344
0.388 89 (76.1) 48 (78.7) 41 (73.2) 0.522 0.109
0.029* 0.041* 0.003*
63 (53.8) 27 (44.3) 36 (64.3)
54 (46.2) 34 (55.7) 20 (35.7)
0.525 38 (32.5) 24 (39.3) 14 (25.0) 0.116 0.270
0.230 32 (27.4) 18 (29.5) 14 (25.0) 0.679 1.000
s are presented as the number of patients followed by percentages in
g the course of their disease. c Patients who had metastatic disease after
tween the cetuximab and chemotherapy groups. ECOG, Eastern Cooperative
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in combination with chemotherapy in first-, second-, or
third-line settings [20]. Only patients with metastatic colo-
rectal cancer (mCRC) expressing wild-type KRAS respond
to cetuximab and show improvements in progression-free
survival (PFS) and overall survival (OS) [21]. KRAS mu-
tations and the B-Raf proto-oncogene, serine/threonine
kinase (BRAF) V600E mutation, the key molecules of
the epidermal growth factor (EGF) pathway, are predic-
tors of resistance to cetuximab therapy [21–23].
It remains unknown whether the primary tumor loca-
tion affects the response of mCRC patients to first- and
second-line cetuximab treatments. This retrospective
multicenter study aimed to investigate the association of
the tumor location with tumor response to cetuximab
and survival in mCRC patients.Table 2 Baseline clinicopathologic characteristics of patients with se
Clinicopathologic characteristic Cetuximab group
All patients RSCC LSCRC
No. of patients 96 28 68
Median age at diagnosis
≤65 years 82 (85.4) 21 (75.0) 61 (89
>65 years 14 (14.6) 7 (25.0) 7 (10
Sex
Male 63 (65.6) 20 (71.4) 43 (63
Female 33 (34.4) 8 (28.6) 25 (36
ECOG performance status
0 53 (55.2) 13 (46.4) 40 (58
1 35 (36.5) 11 (39.3) 24 (35
≥2 8 (8.3) 4 (14.3) 4 (5.9
Pathology
Adenocarcinoma 84 (87.5) 22 (78.6) 62 (91
Mucinous & signet-ring cell 12 (12.5) 6 (21.4) 6 (8.8
Metastasis
Single 69 (71.9) 21 (75.0) 48 (70
Multiple 27 (28.1) 7 (25.0) 20 (29
Metastasis resection 24 (25.0) 6 (21.4) 18 (26
Total cycles of cetuximab (median) 5 (2-20) 4 (2-13) 5 (2-2
Total cycles of chemotherapy (median) 8 (2-66) 7 (4-35) 8 (2-6
All three active drugsa 87 (90.6) 24 (85.7) 63 (92
Backbone chemotherapy
Oxaliplatin-based 27 (28.1) 11 (39.3) 16 (23
Irinotecan-based 69 (71.9) 17 (60.7) 52 (76
Bevacizumab during the disease 27 (28.1) 11 (39.3) 16 (23
Recurrent diseaseb 42 (43.8) 6 (21.4) 36 (52
All values are presented as the number of patients followed by percentages in parenth
course of their disease. b Patients who had metastatic disease after curative-inten
the cetuximab and chemotherapy groups. Other footnotes as in Table 1Patients and methods
Patients and treatment
In this retrospective study, we assessed mCRC patients
treated with cetuximab plus chemotherapy as a first- or
second-line therapy at two national cancer centers (Sun
Yat-sen University Cancer Center and Fudan University
Cancer Center) between January 2006 and December
2013 (the cetuximab group). Similar numbers of patients
with LSCRC and RSCC who received first- or second-
line chemotherapy without cetuximab during the same
period were included as the chemotherapy alone group
by means of isometric mechanical random sampling
as control groups. Enrolled patients have received
mFOLFOX-6 (oxaliplatin 85 mg/m2 d1, 5-fluorouracil [5-
FU] bolus 400 mg/ m2 d1, 5-FU 2,400 mg/m2 continuous
infusion for 46 hours every 2 weeks), XELOX (oxaliplatincond-line treatment
Chemotherapy alone group P valuec
P value All patients RSCC LSCRC P value
— 93 44 49 — 0.011*
.7) 0.108 72 (77.4) 30 (68.2) 42 (85.7) 0.051 0.191
.3) 21 (22.6) 14 (31.8) 7 (14.3)
0.488 1.000 0.105
.2) 50 (53.8) 24 (54.5) 26 (53.1)
.8) 43 (46.2) 20 (45.5) 23 (46.9)
0.074 0.438 0.310
.8) 41 (44.0) 19 (43.2) 22 (44.9)
.3) 42 (45.2) 22 (50.0) 20 (40.8)
) 10 (10.8) 3 (6.8) 7 (14.3)
0.102 0.183 0.822
.2) 83 (89.2) 37 (84.1) 46 (93.9)
) 10 (10.8) 7 (15.9) 3 (6.1)
0.804 1.000 0.005*
.6) 48 (51.6) 23 (52.3) 25 (51.0)
.4) 45 (48.4) 21 (47.7) 24 (49.0)
.5) 0.796 16 (17.2) 11 (25.0) 15 (30.6) 0.646 0.215
0) 0.272 — — — — —
6) 0.548 6 (2-36) 6 (2-36) 6 (2-27) 1.000 0.031*
.6) 0.441 84 (90.3) 39 (88.6) 45 (91.8) 0.731 1.000
0.139 1.000 0.745
.5) 24 (25.8) 11 (25.0) 13 (26.5)
.5) 69 (74.2) 33 (75.0) 36 (73.5)
.5) 0.637 22 (23.7) 8 (18.2) 14 (28.6) 0.329 0.510
.9) 0.006* 33 (35.5) 19 (43.2) 14 (28.6) 0.199 0.298
eses. a Patients who received 5-fluorouracil, oxaliplatin, and irinotecan during the
t primary tumor resection. c Patient characteristics were compared between
Table 4 Objective response rates to first- and second-line
treatments in patients who received chemotherapy alone
Response Fist-line treatment Second-line treatment
RSCC LSCRC RSCC LSCRC
Total 61 56 44 49
Best ORR 16 (26.2) 16 (28.6) 5 (11.4) 5 (10.2)
CR 3 (4.9) 0 (0) 0 (0) 0 (0)
PR 13 (21.3) 16 (28.6) 5 (11.4) 5 (10.2)
SD 28 (45.9) 28 (50.0) 21 (47.7) 23 (46.9)
PD 14 (23.0) 12 (21.4) 16 (36.4) 19 (38.8)
NA 3 (4.9) 0 (0) 2 (4.5) 2 (4.1)
P valuea 0.837 1.000
a The ORR was compared between the RSCC and LSCRC patients who received
chemotherapy alone. Footnotes as in Tables 1 and 3
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3 weeks), or modified FOLFIRI (irinotecan 180 mg/m2 d1,
5-FU bolus 400 mg/m2 d1, 5-FU 2,400 mg/m2 continuous
infusion for 46 hours every 2 weeks) and in combination
with 5-FU–based regimens (cetuximab 400 mg/m2 taken
at the first dose and followed by 500 mg/m2 every 2 weeks)
or capecitabine-based regimens (capecitabine 750 mg/m2
every 3 weeks) in the cetuximab group. All patients had
histologically proven mCRC and offered written informed
consent for possible future data analysis before treatment.
Colon cancers arising in or proximal to the splenic flexure
were defined as RSCCs, and those arising distal to the
splenic flexure were defined as LSCRCs. Clinicpathologic
characteristics (patient age, sex, performance status, and
pathologic subtype), curative-intent metastasis resection,
treatment duration of chemotherapy, and cetuximab,
backbone chemotherapy regimen, exposure to three active
chemotherapy agents, exposure to bevacizumab therapy,
disease-free survival after curative-intent primary tumor
resection, and follow-up data were compared between pa-
tients with LSCRCs and those with RSCCs. The tumor re-
sponse was evaluated by computerized tomodensitometry
according to the Response Evaluation Criteria in Solid
Tumors (RECIST) version 1.1. Objective response rate
(ORR) was defined as percentage of patients showing
complete response (CR) or partial response (PR) as best
response according to RECIST.
Statistical analysis
The patient characteristics and response rates were com-
pared by using Student’s t test or the chi-square test.
The PFS was calculated from the initiation of a first- or
second-line treatment to the date of tumor progression,Table 3 Objective response rate to first-line treatment in










Total 61 33 56 77
Best ORR 16 (26.2) 12 (36.4) 16 (28.6) 38 (49.4)
CR 3 (4.9) 0 (0) 0 (0) 1 (1.3)
PR 13 (21.3) 12 (36.4) 16 (28.6) 37 (48.1)
SD 28 (45.9) 11 (33.3) 28 (50.0) 33 (42.8)
PD 14 (23.0) 10 (30.3) 12 (21.4) 4 (5.2)
NA 3 (4.9) 0 (0) 0 (0) 2 (2.6)
P value a 0.349 0.005
All values are presented as the number of patients followed by the
percentages in parentheses
a The ORR to the first-line treatment was compared between the chemotherapy
and cetuximab plus chemotherapy groups in RSCC and LSCRC
patients, respectively
ORR, objective response rate; CR, complete response; PR, partial response; SD,
stable disease; PD, progressive disease; NA, not available. Other footnotes as
in Table 1death from any cause, or the last follow-up. The OS was
defined as the duration from the start of a first- or
second-line therapy to death of any cause or the date of
the last follow-up. All point data were censored. Both
the PFS and OS were estimated by using the Kaplan-
Meier method and compared by using the log-rank test.
Statistical analysis was performed by using SPSS soft-
ware 19.0 (SPSS Inc., Chicago, IL, USA). The level of
significance was set at P = 0.05.
Results
Patient characteristics
A total of 206 mCRC patients who received combination
treatment with cetuximab and chemotherapy as a first-
line (110 patients) or second-line (96 patients) therapy
were included in this study. In addition, 210 mCRC pa-
tients were chosen as controls from those who received
first-line (117 patients) or second-line chemotherapy
(93 patients) without receiving cetuximab during the
same period. The clinicopathologic characteristics of
these patients are shown in Tables 1 and 2. In patientsTable 5 Objective response rates of first- and second-line
treatments in patients who received cetuximab plus
chemotherapy
Response Fist-line treatment Second-line treatment
RSCC LSCRC RSCC LSCRC
Total 33 77 28 68
Best ORR 12 (36.4) 38 (49.4) 2 (7.1) 16 (23.5)
CR 0 (0) 1 (1.3) 0 (0) 1 (1.5)
PR 12 (36.4) 37 (48.1) 2 (7.1) 15 (22.0)
SD 11 (33.3) 33 (42.8) 16 (57.2) 34 (50.0)
PD 10 (30.3) 4 (5.2) 10 (35.7) 17 (25.0)
NA 0 (0) 2 (2.6) 0 (0) 1 (1.5)
P valuea 0.296 0.085
a The ORR was compared between RSCC and LSCRC patients who received
chemotherapy alone. Other footnotes as in Tables 1 and 3
Fig. 1 Kaplan–Meier survival estimates of metastatic colorectal cancer patie
right-sided colon cancer (RSCC) patients. b, overall survival (OS) curves of R
patients. d, OS curves of LSCRC patients
Table 6 Objective response rates to second-line treatment in










Total 44 28 49 68
Best ORR 5 (11.4) 2 (7.1) 5 (10.2) 16 (23.5)
CR 0 (0) 0 (0) 0 (0) 1 (1.4)
PR 5 (11.4) 2 (7.1) 5 (10.2) 15 (22.1)
SD 21 (47.7) 16 (57.2) 23 (46.9) 34 (50.0)
PD 16 (36.4) 10 (35.7) 19 (38.8) 17 (25.0)
NA 2 (4.5) 0 (0) 2 (4.1) 1 (1.5)
P value a 0.698 0.087
a The ORR to the second-line treatment was compared between the
chemotherapy and cetuximab plus chemotherapy groups of RSCC and
LSCRC patients, respectively.
Other footnotes as in Tables 1 and 3
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the backbone chemotherapy were well-balanced be-
tween the cetuximab group and the chemotherapy
alone group (Table 1).
For the first-line therapy, more patients in the chemo-
therapy alone group received oxaliplatin-based chemo-
therapy than those in the cetuximab group (53.8 % vs.
33.6 %, P = 0.003). By contrast, in those who received
second-line therapy, more patients in the cetuximab
group had single organ metastasis (71.9 % vs. 51.6 %,
P = 0.005) than those in the chemotherapy alone group.
In addition, patients in the cetuximab group had a lon-
ger duration of chemotherapy administration as second-
line therapy (8 vs. 6 cycles, P = 0.031) than those in the
chemotherapy alone group.
Patients were separated into two subgroups (RSCC and
LSCRC) according to the primary tumor location. In the
first-line therapy subgroup (Table 1), age, sex, Eastern Co-
operative Oncology Group (ECOG) performance status,
tumor grade, location of metastasis, resection of thents with first-line therapy. a, progression-free survival (PFS) curves of
SCC patients. c, PFS curves of left-sided colorectal cancer (LSCRC)
Wang et al. Chinese Journal of Cancer  (2015) 34:24 Page 6 of 10primary or metastatic site, total cycles of cetuximab or
chemotherapy, percentage of three active chemotherapy
drugs (5-fluorouracil [FU], oxaliplatin, and irinotecan),
treatment with bevacizumab, and recurrent disease did
not differ between patients with RSCC and those with
LSCRC in both the cetuximab group and the chemother-
apy alone group. The proportion of mucinous or signet-
ring cell carcinomas was significantly higher in patients
with RSCC than in patients with LSCRC in the cetuximab
group (21.2 % vs. 2.6 %, P = 0.003). The proportion of pa-
tients with multiple metastases was significantly higher in
patients with LSCRC than in those with RSCC in the
chemotherapy alone group (51.8 % vs. 29.5 %, P = 0.015).
More patients with RSCC received irinotecan-based first-
line chemotherapy than patients with LSCRC in either the
cetuximab group (81.8 % vs. 59.7 %, P = 0.029) or in the
chemotherapy alone group (55.7 % vs. 35.7 %, P = 0.041)
ORR
As a first-line treatment, the addition of cetuximab to
chemotherapy significantly improved the ORR comparedFig. 2 Kaplan–Meier survival estimates of metastatic colorectal cancer patie
curves of RSCC patients. c, PFS curves of LSCRC patients. d, OS curves of LSwith chemotherapy alone in patients with LSCRC
(49.4 % vs. 28.6 %, P = 0.005) (Table 3). However, the
ORR was comparable between the two groups in pa-
tients with RSCC (36.4 % vs. 26.2 %, P = 0.349). There
was no significant difference in the response rate be-
tween patients with LSCRC and those with RSCC in
both the chemotherapy alone group (28.6 % vs. 26.2 %,
P = 0.837) and the cetuximab group (49.4 % vs. 36.4 %,
P = 0.296) (Tables 4 and 5, respectively).
As a second-line treatment, cetuximab with chemo-
therapy had a tendency to improve the ORR compared
with chemotherapy alone in patients with LSCRC
(23.5 % vs. 7.1 %, P = 0.085), but not in those with
RSCC (7.1 % vs. 11.4 %, P = 0.698) (Table 6). Although
there was no difference in response rate between pa-
tients with LSCRC and RSCC treated with chemother-
apy alone (10.2 % vs. 11.4 %, P = 1.000), cetuximab
with chemotherapy exhibited a trend of improving re-
sponse rate in patients with LSCRC compared with
those with RSCC (23.5 % vs. 7.1 %, P = 0.085) (Tables 4
and 5, respectively).nts with second-line therapy. a, PFS curves of RSCC patients. b, OS
CRC patients
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In RSCC patients who received first-line chemotherapy,
the median PFS (5.6 vs. 5.7 months, P = 0.904) (Fig. 1a)
and OS (25.1 vs. 19.8 months, P = 0.553) (Fig. 1b) were
comparable between those who received cetuximab with
chemotherapy and chemotherapy alone. On the other
hand, first-line treatment with cetuximab plus chemo-
therapy resulted in a significantly longer median PFS
(9.1 vs. 6.2 months, P = 0.002) (Fig. 1c) and OS (28.9 vs.
20.1 months, P = 0.036) (Fig. 1d) compared with chemo-
therapy alone in patients with LSCRC.
For second-line therapy, the addition of cetuximab
treatment did not prolong the median PFS (3.3 vs.
4.2 months, P = 0.761) (Fig. 2a) or OS (13.4 vs. 13.0 months,
P = 0.652) (Fig. 2b) in patients with RSCC. However, in pa-
tients with LSCRC, the combination of cetuximab with
chemotherapy had a tendency to prolong the median
PFS (4.9 vs. 3.5 months, P = 0.064) (Fig. 2c), and it sig-
nificantly prolonged the OS (17.1 vs. 12.4 months, P =
0.047) (Fig. 2d).Fig. 3 Kaplan–Meier survival estimates of metastatic colorectal cancer patie
received first-line therapy. b, OS curves of patients who received first-line th
d, OS curves of patients who received second-line therapyWe also compared the PFS and OS of patients undergo-
ing chemotherapy alone between RSCC and LSCRC
groups. No difference in survival was observed between the
RSCC and LSCRC patients who received chemotherapy
alone as a first-line (PFS, 5.7 vs. 6.2 months, P = 0.160; OS,
19.8 vs. 20.1 months, P = 0.593; Fig. 3a and b) or second-
line therapy (PFS, 4.2 vs. 3.5 months, P = 0.874; OS, 13.0 vs.
12.4 months, P = 0.672; Fig. 3c and d). Similarly, no differ-
ence in survival was observed between the RSCC and
LSCRC patients who received cetuximab combined with
chemotherapy as a first-line (PFS, 5.6 vs. 9.1 months, P =
0.244; OS, 25.1 vs. 28.9 months, P = 0.512; Fig. 4a and b) or
second-line therapy (PFS, 3.3 vs. 4.9 months, P = 0.723; OS,
13.4 vs. 17.1 months, P = 0.120; Fig. 4c and d).
Discussion
The current study showed a significant difference in the
ORR and OS between patients with metastatic LSCRC
and RSCC who underwent first- or second-line cetuximab
treatment. Patients with metastatic LSCRC exhibited ants treated with chemotherapy alone. a, PFS curves of patients who
erapy. c, PFS curves of patients who received second-line therapy.
Fig. 4 Kaplan–Meier survival estimates of metastatic colorectal cancer patients treated with cetuximab plus chemotherapy. a, PFS curves of
patients who received first-line therapy. b, OS curves of patients who received first-line therapy. c, PFS curves of patients who received second-line
therapy. d, OS curves of patients who received second-line therapy
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than to chemotherapy alone, and cetuximab significantly
prolonged the PFS and OS in these patients. However, this
improvement in the OS or PFS was not observed in pa-
tients with RSCC who were treated with cetuximab.
The difference in the response to chemotherapy between
LSCRC and RSCC groups was previously reported. How-
ever, the current study did not observe a different response
to chemotherapy between patients with LSCRC and RSCC.
The combination of cetuximab with chemotherapy had a
tendency to improve the response rate in LSCRC patients
compared with RSCC patients. One study reported that
men with right-sided Duke’s C colon cancer benefited from
adjuvant chemotherapy, but men with left-sided tumors
did not [24]. The study also found a significantly higher
frequency of MSI in right-sided than in left-sided tumors
(20 % vs. 1 %). In the AIO KRK-0104 trial which investi-
gated first-line therapy for mCRC with cetuximab, capecit-
abine, and irinotecan versus cetuximab, capecitabine, and
oxaliplatin, LSCRC was associated with a significantlylonger OS and PFS compared with RSCC [25]. A recent
study of pre-treated, chemotherapy-refractory mCRC pa-
tients showed that cetuximab was associated with a longer
PFS compared with best support care in patients with
LSCRC (5.4 vs. 1.8 months, P < 0.001), but not in those
with RSCC (1.9 vs. 1.9 months, P = 0.26) [26].
Although the current study observed an interesting
phenomenon, it needs to be confirmed in a randomized
prospective study. The underlying mechanisms for the
differences in the response rates between LSCRC and
RSCC remain unclear. Because the benefit of cetuximab
is limited to mCRC patients with wild-type KRAS tu-
mors, the KRAS status in both LSCRC and RSCC needs
to be taken into consideration [27]. Several studies found
a higher rate of KRAS mutations in RSCC than that in
LSCRC [14, 15]. Other studies found similar KRAS mu-
tation rates in both RSCC and LSCRC [8, 16]. In
addition to KRAS, the BRAF V600E mutation negatively
impacts the treatment outcomes for cetuximab in mCRC
patients [23]. The BRAF mutation is observed more
Wang et al. Chinese Journal of Cancer  (2015) 34:24 Page 9 of 10frequently in RSCC than in LSCRC, which might partly
explain the higher response rate to cetuximab in patients
with LSCRC [16, 28]. However, the NRAS mutation is
mainly found in LSCRC [29]. Alterations of other mole-
cules, including EGFR polysomy, EGFR amplification,
and phosphatase and tensin homolog (PTEN) null ex-
pression, have been found to be associated with the out-
come of cetuximab treatment [30].
Conclusions
In conclusion, the current study suggests that the pri-
mary tumor location may affect the response of patients
with mCRC to cetuximab. The addition of cetuximab to
first-line and second-line chemotherapy may only benefit
patients with metastatic LSCRC. These results should be
further confirmed in a prospective study.
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